Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (912)	3/31/1998 10:50:00 PM
From: Fred Levine	Read Replies (1) \| Respond to of 1605

EECP has, from the first study, demonstrated improved clinical and physiological functioning. The patients initially selected were those that were resistant to other forms of intervention, and had a 3 year survival rate of 88%. That study, as far as I can recall, did not have a control group. I have all the research in my car and will review it tomorrow. I think that even if the morbidity rate were identical to other forms of intervention, the noninvasive character of the treatment and lower expense are benefits. I have a vital (as well as financial)interest in the answer to the morbidity question. good investing and health -- fred